Analysts Set Annovis Bio, Inc. (NYSE:ANVS) Price Target at $31.40

Shares of Annovis Bio, Inc. (NYSE:ANVSGet Free Report) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $31.40.

Several research analysts have recently commented on the company. Maxim Group upgraded Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Monday, November 11th.

Get Our Latest Research Report on Annovis Bio

Institutional Investors Weigh In On Annovis Bio

Large investors have recently added to or reduced their stakes in the stock. Merit Financial Group LLC boosted its holdings in shares of Annovis Bio by 269.0% during the fourth quarter. Merit Financial Group LLC now owns 98,516 shares of the company’s stock valued at $496,000 after acquiring an additional 71,816 shares during the period. Quest Partners LLC bought a new position in Annovis Bio in the 3rd quarter worth about $371,000. Geode Capital Management LLC raised its holdings in shares of Annovis Bio by 30.0% during the third quarter. Geode Capital Management LLC now owns 99,114 shares of the company’s stock valued at $799,000 after buying an additional 22,881 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of Annovis Bio during the fourth quarter worth approximately $65,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Annovis Bio in the 3rd quarter valued at approximately $76,000. 15.83% of the stock is owned by institutional investors and hedge funds.

Annovis Bio Price Performance

ANVS opened at $2.94 on Wednesday. The stock has a market capitalization of $41.87 million, a PE ratio of -0.66 and a beta of 1.63. Annovis Bio has a 12-month low of $2.88 and a 12-month high of $20.00. The firm’s fifty day moving average price is $4.98 and its 200 day moving average price is $7.18.

Annovis Bio (NYSE:ANVSGet Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.33). On average, equities research analysts forecast that Annovis Bio will post -2.19 earnings per share for the current fiscal year.

Annovis Bio Company Profile

(Get Free Report

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

Recommended Stories

Analyst Recommendations for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.